AU2001287103B2 - EIAV chimeric vaccine and diagnostic - Google Patents

EIAV chimeric vaccine and diagnostic Download PDF

Info

Publication number
AU2001287103B2
AU2001287103B2 AU2001287103A AU2001287103A AU2001287103B2 AU 2001287103 B2 AU2001287103 B2 AU 2001287103B2 AU 2001287103 A AU2001287103 A AU 2001287103A AU 2001287103 A AU2001287103 A AU 2001287103A AU 2001287103 B2 AU2001287103 B2 AU 2001287103B2
Authority
AU
Australia
Prior art keywords
gene
eiav
vaccine
deleted
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2001287103A
Other languages
English (en)
Other versions
AU2001287103A1 (en
Inventor
Karen K. Brown
Jodi Craigo
Kristina J. Hennessey
Charles Issel
Ronald C. Montelaro
Bridget Puffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intervet International BV
Original Assignee
Intervet International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet International BV filed Critical Intervet International BV
Publication of AU2001287103A1 publication Critical patent/AU2001287103A1/en
Application granted granted Critical
Publication of AU2001287103B2 publication Critical patent/AU2001287103B2/en
Priority to AU2007201936A priority Critical patent/AU2007201936A1/en
Assigned to INTERVET INTERNATIONAL B.V. reassignment INTERVET INTERNATIONAL B.V. Request for Assignment Assignors: AKZO NOBEL N.V.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2001287103A 2000-09-09 2001-09-06 EIAV chimeric vaccine and diagnostic Ceased AU2001287103B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007201936A AU2007201936A1 (en) 2000-09-09 2007-05-01 EIAV Chimeric Vaccine and Diagnostic

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US65902900A 2000-09-09 2000-09-09
US09/659,029 2000-09-09
PCT/US2001/027599 WO2002020049A2 (en) 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007201936A Division AU2007201936A1 (en) 2000-09-09 2007-05-01 EIAV Chimeric Vaccine and Diagnostic

Publications (2)

Publication Number Publication Date
AU2001287103A1 AU2001287103A1 (en) 2002-06-13
AU2001287103B2 true AU2001287103B2 (en) 2007-02-01

Family

ID=24643739

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001287103A Ceased AU2001287103B2 (en) 2000-09-09 2001-09-06 EIAV chimeric vaccine and diagnostic
AU8710301A Pending AU8710301A (en) 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU8710301A Pending AU8710301A (en) 2000-09-09 2001-09-06 Eiav chimeric vaccine and diagnostic

Country Status (5)

Country Link
EP (1) EP1345622A2 (OSRAM)
JP (1) JP2004522697A (OSRAM)
AU (2) AU2001287103B2 (OSRAM)
BR (1) BR0113745A (OSRAM)
WO (1) WO2002020049A2 (OSRAM)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873690A (en) * 1974-01-23 1975-03-25 Iii James H Rand Equine infectious anemia vaccine
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
WO1998051810A1 (en) * 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5955342A (en) * 1994-08-15 1999-09-21 Connaught Laboratories Limited Non-infectious, replication-defective, self-assembling HIV-1 viral particles containing antigenic markers in the gag coding region
EP0991771A2 (en) * 1997-03-06 2000-04-12 Klaus Überla Lentivirus based vector and vector system
ATE528405T1 (de) * 1997-12-22 2011-10-15 Oxford Biomedica Ltd Auf dem virus der infektiösen pferdeanämie (eiav) basierende vektoren
CN1173036C (zh) * 1999-04-21 2004-10-27 卫生部艾滋病预防与控制中心 马传染性贫血病毒驴白细胞弱毒疫苗株的全长基因序列

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3873690A (en) * 1974-01-23 1975-03-25 Iii James H Rand Equine infectious anemia vaccine
US5614404A (en) * 1988-06-10 1997-03-25 Theriod Biologics, Incorporated Self-assembled, defective, non-self-propagating lentivirus particles
WO1998051810A1 (en) * 1997-05-13 1998-11-19 University Of North Carolina At Chapel Hill Lentivirus-based gene transfer vectors

Also Published As

Publication number Publication date
JP2004522697A (ja) 2004-07-29
AU8710301A (en) 2002-03-22
WO2002020049A3 (en) 2003-07-03
BR0113745A (pt) 2004-03-02
WO2002020049A2 (en) 2002-03-14
EP1345622A2 (en) 2003-09-24

Similar Documents

Publication Publication Date Title
US11098084B2 (en) Virus-like particles and methods of use
Montelaro et al. Equine retroviruses
EP2370455B1 (en) Virus like particle compositions and methods of use
JP2023513913A (ja) 麻疹ベクターを用いたｃｏｖｉｄ－１９免疫原性組成物及びワクチン
KR20000070865A (ko) 합성 ＨＩＶ ｇａｇ 유전자
KR20080066042A (ko) 렌티바이러스 벡터 기반 백신
US20090123494A1 (en) Momlv-based pseudovirion packaging cell line
Dollenmaier et al. Membrane-associated respiratory syncytial virus F protein expressed from a human rhinovirus type 14 vector is immunogenic
US6727078B2 (en) EIAV p26 deletion vaccine and diagnostic
Gorelick et al. Protection of Macaca nemestrina from disease following pathogenic simian immunodeficiency virus (SIV) challenge: utilization of SIV nucleocapsid mutant DNA vaccines with and without an SIV protein boost
WO2012038832A2 (en) Generation of replicating chimeric measles virus - retrovirus particles
WO2019123018A2 (en) Lassa vaccine
AU2001287103B2 (en) EIAV chimeric vaccine and diagnostic
Ma et al. A proviral derivative from a reference attenuated EIAV vaccine strain failed to elicit protective immunity
Race et al. An experimental chemically inactivated HIV-1 vaccine induces antibodies that neutralize homologous and heterologous viruses
AU2007201936A1 (en) EIAV Chimeric Vaccine and Diagnostic
US9566329B2 (en) Live, attenuated rubella vector to express vaccine antigens
Jurgens et al. A novel self-replicating chimeric lentivirus-like particle
CA2330618C (en) Viral chimeras comprised of caev and hiv-1 genetic elements
AU2001287103A1 (en) EIAV chimeric vaccine and diagnostic
US20130337009A1 (en) Chimeric dna vaccine compositions and methods of use
Zheng et al. Replication ability in vitro and in vivo of equine infectious anemia virus avirulent Japanese strain
US9181306B2 (en) Insertion of foreign genes in rubella virus and their stable expression in a live, attenuated viral vaccine
Horiuchi et al. DNA vaccination of macaques by a full-genome SHIV plasmid that has an IL-2 gene and produces non-infectious virus particles
Zabihollahi et al. Introducing a frameshift mutation to the POL sequence of HIV-1 provirus and evaluation of the immunogenic characteristics of the mutated virions (RINNL4-3)

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: INTERVET INTERNATIONAL B.V.

Free format text: FORMER OWNER WAS: AKZO NOBEL N.V.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired